Immix Biopharma — Full steam ahead with US CAR-T trial

Immix Biopharma (NASDAQ: IMMX)

Last close As at 10/10/2024

USD1.54

0.01 (0.65%)

Market capitalisation

USD42m

More on this equity

Research: Healthcare

Immix Biopharma — Full steam ahead with US CAR-T trial

Immix Biopharma’s second quarter was headlined by intensified clinical activity for lead CAR-T asset NXC-201 (targeting amyloid light chain amyloidosis, ALA), followed by commencement of patient dosing in the US-based NEXICART-2 trial in July 2024. With an 18- to 24-month timeline for full trial enrollment (planned n=40) and top-line data expected in Q2/Q326, we now anticipate a biological license application (BLA) to be filed in H127 (vs 2026 previously). In our view, the development path has been partially de-risked by the potential $8m grant inflows from the California Institute for Regenerative Medicine (CIRM), which should bolster liquidity and extend the operational runway to Q425. We adjust our top-line estimates to reflect grant inflows but conservatively push out the NXC-201 launch timeline to 2028 (vs 2027 previously). We revise our valuation to $123.1m or $4.5/share (from $139.5m or $5.3/share).

Soo Romanoff

Written by

Soo Romanoff

Managing Director - Head of Content, Healthcare

Cancer cells low poly blue

Healthcare

Immix Biopharma

Full steam ahead with US CAR-T trial

Q224 results

Pharma and biotech

14 August 2024

Price

US$1.86

Market cap

US$51m

Net cash (US$m) at 30 June 2024

24.0

Shares in issue

27.5m

Free float

42%

Code

IMMX

Primary exchange

Nasdaq

Secondary exchange

N/A

Share price performance

%

1m

3m

12m

Abs

(11.8)

(13.9)

2.2

Rel (local)

(8.9)

(17.3)

(16.1)

52-week high/low

US$7.3

US$1.6

Business description

Immix Biopharma is a clinical-stage biopharma developing personalized therapies for oncology and immunology. Lead asset NXC-201 is a BCMA-targeting CAR-T asset, being evaluated for amyloid light chain amyloidosis and multiple myeloma with plans to expand to autoimmune indications. Legacy asset IMX-110 is being investigated in a Phase Ib/IIa study in soft tissue sarcoma and a Phase Ib/IIa trial for solid tumors in combination with tislelizumab.

Next events

NEXICART-2 initial data (ALA)

Q424

Additional autoimmune indications announced for NXC-201

H224

NXC-201 interim data (undisclosed autoimmune indications)

Q425

Analysts

Soo Romanoff

+44 (0)20 3077 5700

Dr Arron Aatkar

+44 (0)20 3077 5700

Jyoti Prakash, CFA

+44 (0)20 3077 5700

Immix Biopharma is a research client of Edison Investment Research Limited

Immix Biopharma’s second quarter was headlined by intensified clinical activity for lead CAR-T asset NXC-201 (targeting amyloid light chain amyloidosis, ALA), followed by commencement of patient dosing in the US-based NEXICART-2 trial in July 2024. With an 18- to 24-month timeline for full trial enrollment (planned n=40) and top-line data expected in Q2/Q326, we now anticipate a biological license application (BLA) to be filed in H127 (vs 2026 previously). In our view, the development path has been partially de-risked by the potential $8m grant inflows from the California Institute for Regenerative Medicine (CIRM), which should bolster liquidity and extend the operational runway to Q425. We adjust our top-line estimates to reflect grant inflows but conservatively push out the NXC-201 launch timeline to 2028 (vs 2027 previously). We revise our valuation to $123.1m or $4.5/share (from $139.5m or $5.3/share).

Year
end

Revenue
(US$m)

PBT*
(US$m)

EPS*
(US$)

DPS
(US$)

P/E
(x)

Yield
(%)

12/22

0.0

(7.60)

(0.55)

0.0

N/A

N/A

12/23

0.0

(13.00)

(0.75)

0.0

N/A

N/A

12/24e

2.0

(16.59)

(0.61)

0.0

N/A

N/A

12/25e

6.0

(17.06)

(0.58)

0.0

N/A

N/A

Note: *PBT and EPS are normalized, excluding amortization of acquired intangibles, exceptional items and share-based payments.

NEXICART-2 gets off the blocks

The NEXICART-2 trial is Immix’s primary near-term focus, and we see the recent (July 2024) commencement of patient dosing as an important step towards achieving its goal to develop the first outpatient CAR-T treatment for relapsed/refractory ALA (r/r ALA). The Phase Ib US study aims to recruit a total of 40 patients within 18–24 months and the company expects to report top-line readouts in Q2/Q326. As we account for the time required to conduct the data analysis after the final readouts, we now conservatively expect Immix to be able to file a BLA with the FDA in H127, with a launch potentially in 2028, should the trial data be supportive.

New grant to provide additional headroom

Given the capital-intensive nature of CAR-T trials (per-patient costs are upwards of $500k) we expect the $8m grant from the CIRM to partially de-risk the development plan, while also providing external validation to Immix’s efforts in the CAR-T field. We expect the funds, if fully disbursed (payments expected from September 2024), to extend the cash runway to Q425. We estimate that the company will raise a further $15m across H225 and 2026, with a potential partnership deal thereafter.

Valuation: Revised to $123.1m or $4.5/share

We update our estimates for the latest cash position and potential grant receipts from CIRM (modelling $2m in inflows in H224 and $6m in 2025), noting that such payments are subject to meeting certain enrollment-related milestones. Based on the updated trial readout timelines, we also conservatively extend our launch timelines for NXC-201 in ALA to 2028, from 2027 previously. We adjust our valuation to $123.1m or $4.5/share, from $139.5m or $5.3/share previously.

NEXICART-2 progressing according to plan

US trial kicks off with first patient dosed

Q224 was an active period for Immix, with intensive preparatory work for the initiation of the US-based NEXICART-2 trial allowing for the first patient dosing in July 2024 (consistent with the previously communicated mid-2024 target). As a reminder, the NEXICART-2 trial is a follow-up study to the ongoing NEXICART-1 study, which was based in Israel, but with the trial design and patient profiling optimized (based on key takeaways from NEXICART-1) to ensure the maximum likelihood of patient benefit and trial success. The choice of r/r ALA as the target indication is also strategic, in our opinion, given the limited treatment options and lack of CAR-Ts being developed for this indication, providing a greenfield opportunity to Immix.

ALA is a rare condition (incidence of c 4,000 per year in the US, c 75% of which are r/r), characterized by misfolded amyloid proteins, which accumulate around tissues and organs, hindering their function. The standard of care includes autologous stem cell transplant or a combination of daratumumab (a CD-38 targeting monoclonal antibody) and CyBorD (chemotherapy agents cyclophosphamide, bortezomib and dexamethasone), but relapse remains an ongoing medical challenge. While B-cell maturation antigen (BCMA)-targeting CAR-T therapies such as NXC-201 are gaining popularity as a viable treatment option for certain conditions (Bristol Myers Squibb’s (BMS’s) Abecma and Johnson & Johnson’s (J&J’s) Carvykti are BCMA-targeting therapies approved for the treatment of multiple myeloma), the side-effect profile of such treatments limits wider applicability, particularly in indications with fragile patient populations, such as ALA. However, clinical trials to date for NXC-201 have demonstrated a desirable safety profile (1–2 day cytokine release syndrome (CRS), as discussed here, versus 4–8 days for currently approved CAR-Ts).

Exhibit 1 presents an overview of Immix’s CAR-T pipeline.

Exhibit 1: Immix Biopharma’s development pipeline

Source: Immix Biopharma corporate presentation, August 2024

An optimized trial design

NEXICART-2 is a Phase Ib open-label, single-arm, multi-site dose escalation/dose expansion study, aiming to test the safety and efficacy of NXC-201. Based on data analyses from NEXICART-1, the US-based study aims to recruit up to 40 patients with r/r ALA (without concomitant multiple myeloma) with adequate cardiac function (by excluding patients with Mayo stage 3b ALA or New York Heart Association stage 3 or 4 heart failure) and who have not received prior BCMA-targeting treatments. We remind readers that of the 13 ALA patients in NEXICART-1, for whom the trial data were presented at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, five had NYHA stage III/IV heart failure, and five had Mayo stage 3 ALA (the overlap between both groups was not specified). Management expects improved outcomes for patients with better cardiac function, as reflected with the updated trial design. We highlight that despite the more fragile nature of the patient population in NEXICART-1, an overall response rate (ORR) of 92% and a complete response (CR) rate of 75% were achieved, adding confidence to the potential outcome of the NEXICART-2 trial, in our view. (The latest clinical data are discussed in further detail in our prior update note.)

The first dose escalation portion of NEXICART-2 will evaluate two doses (150m CAR-T cells and 450m CAR-T cells) across two cohorts of three patients, with the potential to increase dosing to 800m CAR-T cells in the expansion phase, provided the initial doses are deemed safe. The study will determine the maximum tolerated and recommended Phase II dose, while also evaluating efficacy signals (ORR and CR rate). We note that these doses were all tested successfully in NEXICART-1. For NEXICART-2, Immix aims to complete patient enrolment within 18–24 months with top-line readouts guided in Q2/Q326. Management plans to share an initial data readout in Q424, and a further interim readout in mid-2025, both of which could potentially be major catalysts. In our view, the overriding goal of the US trial will be to improve upon (or at least reproduce) the results seen in NEXICART-1.

CAR-T therapies in the headlines

Despite the headwinds faced by CAR-T therapies after the requirement for black box warnings on current approved products due to risk of secondary malignancies, Immix has assured the market that it has not seen such malignancies in the clinical data to date for NXC-201. Moreover, the FDA indicates that it believes the benefits outweigh the risks, exemplified by its approval to move BMS’s Abecma and J&J/Legend’s Carvykti to earlier-line treatment settings. We also highlight that recent research has characterized the risk of these secondary malignancies as low.

In general, side effects represent a key risk in the development of CAR-T therapies, arguably more so than many other technologies in clinical development. This was recently exemplified with Galapagos having to pause its Phase II BCMA-targeting CAR-T trial, due to the observation of a Parkinsonism adverse event, which has also been seen in recipients of BMS’s and J&J’s BCMA-targeting CAR-T therapies. We believe Immix may be able to offer safety-based differentiation with NXC-201, based on the reported clinical data to date. In addition to the efficacy results discussed above, the company has reported zero cases of neurotoxicity and that cases of CRS showed a low median duration of two days. In our view, NXC-201 has the potential to address the safety limitations of current approved CAR-T therapies, positioning NXC-201 as a possible out-patient treatment.

$8m grant provides additional liquidity

In July 2024, Immix was awarded an $8m grant from the CIRM to advance the clinical development of NXC-201 for the treatment of r/r ALA. The CIRM is a state-funded agency supporting innovation in the field of cell therapies, and we see this as encouraging recognition of Immix’s efforts in the CAR-T space. Moreover, the cash injection should support ongoing clinical activity for NXC-201 and enhance the cash runway by around six months, per our calculations (from Q225 to Q425). However, we note that the payout will be contingent on the company achieving certain clinical milestones, primarily pertaining to patient enrolment in the clinical trials for NXC-201. The company expects to start receiving the funds from September 2024.

Next up: NXC-201 in additional autoimmune indications

While ALA remains the near-term priority for Immix, as part of its strategy to focus on indications not currently targeted by CAR-Ts, management has indicated its intention to target additional autoimmune conditions as a strategic area of interest. While we await an update on the additional selected autoimmune indications (expected to be announced by end-2024), we note that the company is planning single-arm, open-label trials across two unaddressed (and currently undisclosed) autoimmune indications with interim data expected to be reported in Q425. Autoimmune conditions are widely regarded as the next frontier for CAR-T treatments, which, in addition to Immix’s progress in ALA, has been recently explored with an allogeneic CAR-T therapy, based on a study conducted in China and published in Cell. We await further details from management on its plans in this area.

Financials

Immix’s Q224 results were unsurprising, reflecting the company’s efforts towards ramping up clinical activity in the US. The operating loss for the quarter was $4.7m, up 26.4% y-o-y ($3.7m in Q223), although lower than the Q124 figure of $5.6m. Q224 R&D expenses of $2.2m were notably lower than Q124 ($3.2m), which we believe was due to reduced NEXICART-1 activity. With the commencement of patient enrollment for NEXICART-2, we expect this figure to rise in the coming quarters. G&A expenses were $2.5m, up 64% y-o-y, but in line with the numbers recorded in the previous two quarters. The increase was related primarily to higher fees for investor relations ($322.7k), stock-based compensation ($236.2k) and employee compensation ($189.3k). Free cash outflow for the quarter was $5.4m, reflecting the operating performance.

We have adjusted our FY24 and FY25 top-line estimates to reflect the potential inflows from the CIRM grant payment. Management expects the receipts to flow in from September 2024 and we estimate a total of $2m will be received in H224, with the remaining $6m in 2025. We keep our R&D and G&A estimates unchanged, expecting an increase in R&D expenses in H224 ($8.0m vs $5.5m in H124). Overall, our revised operating loss estimates for FY24 and FY25 are $20.0m and $20.2m, respectively (previously $22.0m and $26.2m).

Valuation

We continue to value Immix using a risk-adjusted net present value (rNPV) approach for all assets in clinical development. As previously noted, the near-term development focus for the company will be NXC-201 in r/r ALA, for which there has been a minor shift in reported timelines. Management now expects patient enrollment to be completed within 18–24 months (vs 18 months previously). Immix’s update also states that top-line results can be expected in Q2/Q326 (vs our previous assumption of early-2026). Accounting for the additional time required to prepare the data package for FDA submission and launch preparations (if approved), we have conservatively adjusted our launch timelines for NXC-201 to 2028 (from 2027 previously). Accordingly, we now estimate a partnership deal to be signed in 2027 (vs 2026 previously), although we keep the assumed deal terms unchanged for now. Our revised rNPV for NXC-201 in ALA stands at $37.1m (vs $45.4m previously).

For the other programs, our valuation remains broadly unchanged. While we currently maintain our existing timelines on the other programs (NXC-201 in multiple myeloma and IMX-110 in soft tissue sarcomas and solid tumors), we will revisit our assumptions based on future updates from management on their development plans. We also await further information on the selected additional autoimmune indications for NXC-201 before incorporating them in our valuation, which could provide upside.

Reflecting the aforementioned changes to the NXC-201 launch timeline and the lower period-ending net cash position ($24.0m at Q224 vs $29.3m in our last note), we adjust our valuation for Immix to $123.1m (from $139.5m previously). In addition to this, our per-share valuation is affected by the higher share count (27.5m vs 26.4m previously), resetting at $4.5/share (vs $5.3/share previously). Exhibit 2 presents a breakdown of our rNPV valuation for Immix.

Exhibit 2: Immix Biopharma rNPV

Product

Indication

Launch

Peak

Peak sales (US$m)

Value
(US$m)

Probability

rNPV
(US$m)

rNPV/share* (US$)

NXC-201

Amyloid light chain amyloidosis

2028

2034

347.2

174.9

25.0%

37.1

1.4

NXC-201

Multiple myeloma

2030

2035

293.8

153.4

17.5%

29.4

1.1

IMX-110

Soft tissue sarcoma

2029

2034

452.9

141.7

15.0%

19.7

0.7

IMX-110

Solid tumors

2029

2034

451.2

168.5

10.0%

13.0

0.5

Net cash on 30 June 2024

 

 

 

24.0

100%

24.0

0.9

Valuation

 

 

 

 

662.5

 

123.1

4.5

Source: Edison Investment Research. Note: *The per share valuation uses the shares outstanding figure of 27.5m shares.

We expect the period end cash balance of $24m to be bolstered by the potential receipt of the $8m grant income from CIRM, extending the cash runway by another six months to Q425 (vs Q225 previously) based on our projected cash burn rates. We forecast that the company will raise $5m in H225, and another $10m in 2026, before signing a partnership deal in 2027 with the associated capital injection. Should such a deal not take place, we estimate that the company would need to raise another $10m in FY27, before turning cash flow positive in FY28 following the potential launch of NXC-201 in ALA. If Immix were to raise these funds (a total of $25m across FY25–27) through equity issuance, it would need to issue 13.4m shares (assuming a conversion price of $1.86, based on the last closing price), and our valuation would decrease to $3.6/share (from $4.5/share currently), and the number of shares outstanding would increase to 40.9m from 27.5m currently.

Exhibit 3: Financial summary

Accounts: IFRS; year-end 31 December; US$000s

2022

2023

2024e

2025e

PROFIT & LOSS

 

 

 

 

Total revenues

0

0

2,000

6,000

Cost of sales

0

0

0

0

Gross profit

0

0

2,000

6,000

Total operating expenses

(8,219)

(16,141)

(21,963)

(26,159)

Research and development expenses

(4,196)

(8,735)

(13,446)

(16,790)

SG&A

(4,023)

(7,406)

(8,517)

(9,369)

EBITDA (normalized)

(8,217)

(16,136)

(19,854)

(20,052)

Operating income (reported)

(8,219)

(16,141)

(19,963)

(20,159)

Finance income/(expense)

(0)

572

875

597

Exceptionals and adjustments

0

0

0

0

Profit before tax (reported)

(8,219)

(15,569)

(19,087)

(19,562)

Profit before tax (normalized)

(7,595)

(13,003)

(16,587)

(17,062)

Income tax expense (includes exceptionals)

(10)

(26)

(32)

(33)

Net income (reported)

(8,230)

(15,596)

(19,120)

(19,595)

Net income (normalized)

(7,606)

(13,030)

(16,620)

(17,095)

Basic average number of shares, m

13.9

17.3

27.4

29.4

Basic EPS (US$)

(0.59)

(0.90)

(0.70)

(0.67)

Adjusted EPS (US$)

(0.55)

(0.75)

(0.61)

(0.58)

Dividend per share (US$)

0.00

0.00

0.00

0.00

BALANCE SHEET

 

 

 

 

Property, plant and equipment

4

50

1,426

1,319

Other non-current assets

7

87

87

87

Total non-current assets

10

137

1,513

1,407

Cash and equivalents

13,437

17,510

16,948

4,960

Current tax receivables

256

1,172

1,172

1,172

Other current assets

1,205

1,106

1,106

1,106

Total current assets

14,898

19,788

19,226

7,238

Other non-current liabilities

475

0

1,485

1,485

Long term debt

0

0

0

5,000

Total non-current liabilities

475

0

1,485

6,485

Accounts payable

1,273

3,722

3,722

3,722

Other current liabilities

0

0

0

0

Total current liabilities

1,273

3,722

3,722

3,722

Equity attributable to company

13,160

16,203

15,533

(1,562)

CASH FLOW STATEMENT

 

 

 

 

Net Income

(8,230)

(15,596)

(19,120)

(19,595)

Depreciation and amortization

2

5

109

107

Share based payments

624

2,566

2,500

2,500

Other adjustments

0

0

0

0

Movements in working capital

195

1,653

0

0

Cash from operations (CFO)

(7,408)

(11,371)

(16,511)

(16,988)

Capex

0

(52)

0

0

Acquisitions & disposals net

0

0

0

0

Other investing activities

0

0

0

0

Cash used in investing activities (CFIA)

0

(52)

0

0

Capital changes

2,914

15,521

15,947

0

Debt Changes

0

0

0

5,000

Other financing activities

318

(57)

2

0

Cash from financing activities (CFF)

3,232

15,464

15,950

5,000

Cash and equivalents at beginning of period

17,644

13,437

17,510

16,948

Increase/(decrease) in cash and equivalents

(4,176)

4,040

(562)

(11,988)

Effect of FX on cash and equivalents

(32)

33

0

0

Cash and equivalents at end of period

13,437

17,510

16,948

4,960

Net (debt)/cash

13,437

17,510

16,948

(40)

Source: Company reports, Edison Investment Research


General disclaimer and copyright

This report has been commissioned by Immix Biopharma and prepared and issued by Edison, in consideration of a fee payable by Immix Biopharma. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2024 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

General disclaimer and copyright

This report has been commissioned by Immix Biopharma and prepared and issued by Edison, in consideration of a fee payable by Immix Biopharma. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2024 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

More on Immix Biopharma

View All

Latest from the Healthcare sector

View All Healthcare content

Research: Investment Companies

BB Biotech — Lower rates and news flow to support recovery

BB Biotech (BION) offers investors exposure to the innovative, rapidly expanding biotech sector. It is the largest biotech investor among its investment company peers, focused on high-quality biotech assets that target substantial market opportunities. The company recently released its interim report for the period ended 30 June 2024, which provided an update on recent performance and developments with portfolio companies, and outlined the major milestones expected from these holdings during the second half of 2024. This note summarises the key points from the report, and the reasons why BION’s managers are optimistic about the outlook for the biotech sector and for their portfolio.

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free